Betta Pharmaceuticals has been granted a patent for a bromodomain inhibitor, including specific crystalline forms. The invention covers compositions, formulations, and methods of using and preparing these compounds. GlobalData’s report on Betta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Betta Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Betta Pharmaceuticals's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Bromodomain inhibitor in crystalline form
A recently granted patent (Publication Number: US11845762B2) discloses a crystalline form of a compound with a specific X-ray powder diffraction pattern, as outlined in claims 1 and 2. The crystalline form is characterized by peaks at 2? values of 13.8±0.2°, 18.9±0.2°, and 26.0±0.2°, and may be anhydrous, as specified in claim 3. This unique crystalline form is utilized in claim 4 to formulate a pharmaceutical composition along with a pharmaceutical acceptable excipient, with a defined weight ratio range in claim 5.
Furthermore, the patent claims encompass a method for treating BET-mediated diseases in a subject by administering the crystalline form of claim 1. The BET-mediated diseases listed include various types of leukemia, lymphoma, solid tumors, and other cancers, as detailed in claim 6. The method specifies the involvement of BRD4 in BET-mediated diseases and is intended for human subjects, as indicated in claims 7 and 8. This patent highlights the potential therapeutic applications of the disclosed crystalline form in targeting BET-mediated diseases, particularly in the treatment of various types of cancer in human patients.
To know more about GlobalData’s detailed insights on Betta Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
